In TNBC patients, Zhang et al. have reported no statistical differences in TMB or percent genome alteration in early (≤2 years) versus late/no recurrence groups.18 In our study, we found no significant difference in targetable mutations in early versus late recurrence groups within receptor subtypes but noted that TNBC and stage III cancers tended to recur early while HR+ HER2− cancers and stage I disease tended to recur late. The gene discussed is ERBB2; the disease is cancer.